Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients

Autor(es)

Gouveia, Gisele R. ^[1] ; Ferreira, Suzete C. ^[2] ; Siqueira, Sheila A. C. ^[3] ; de Padua Covas Lage, Luis Alberto ^{[1, 4]} ; Hallack Neto, Abrahao E. ^[5] ; de Oliveira Costa, Renata ^[6] ; Pereira, Juliana ^{[4, 7]}

Afiliação do(s) autor(es)

^[1] Univ Sao Paulos Med Sch FM USP, Lab Med Invest Pathogenesis & Directed Therapy On, Fac Med, Av Dr Eneas Carvalho Aguiar 155, Sao Paulo, SP - Brazil

^[2] Prosangue Fdn, Sao Paulo Blood Bank, Dept Mol Biol, Sao Paulo - Brazil

^[3] Sao Paulo Univ HC FM USP, Fac Med, Hosp Clin, Dept Pathol, Sao Paulo - Brazil

^[4] Sao Paulo Univ FM USP, Fac Med, Dept Hematol Hemotherapy & Cell Therapy, Sao Paulo - Brazil

^[5] Univ Juiz De Fora UJF, Dept Hematol & Hemotherapy, Juiz De Fora - Brazil

^[6] Ctr Univ Lusiadas FCMS UNILUS, Dept Hematol & Hemotherapy, Santos, SP - Brazil

^[7] Nucleus Nonhodgkins Lymphomas & Histiocyt Disorde, Lab Med Invest Pathogenesis & Directed Therapy On, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: BMC CANCER; v. 20, n. 1 OCT 29 2020.
• Citações Web of Science: 0

Resumo

BackgroundOCT-1 gene is a member of the POU-homeodomain family of transcriptional regulators of B-lymphocyte differentiation by controlling expression of B-cell specific genes. BCL-2 gene is a potent inhibitor of apoptosis and it is essential during B-cell differentiation into germinal center. These genes may be expressed in diffuse large B-cell lymphoma (DLBCL), but the role of BCL-2 in its prognosis has been contradictory, and OCT-1 has yet to be tested.MethodsIn this study, we aimed to investigate the prognostic impact of OCT-1 and BCL-2 expression in DLBCL treated in the real world with immunochemotherapy in a single center. BCL-2 and OCT-1 genes were available in 78.5% (77/98) DLBCL patients, and the RNA for quantitative real-time PCR was isolated from formalin-fixed paraffin-embedded samples. The values obtained for gene expression were transformed in categorical variable according to their median.ResultsCohort median age was 54.5years (15-84), 49 (50%) were male, 38/77 (49.4%) and 40/77 (51.9%) presented OCT-1 and BCL-2 expression >= median, respectively. The overall response rate (ORR) in all patients was 68.4% (67/98), 65,3% (64/98) of patients acquired complete response, and 3.1% (3/98) partial response, while 6.1% (6/98) were primary refractory. The median follow-up was 3.77years (95% CI: 3.2-4.1), with 5.43 (95% CI: 2.2-NR) of overall survival (OS) and 5.15years (95% CI: 2.9-NA) of progression free survival (PFS). OCT-1 >= median was associated with shorter OS at univariate analysis (p =0.013; {[}HR] 2.450, 95% CI: 1.21-4.96) and PFS (p =0.019; {[}HR] 2.270, 95%CI: 1.14-4.51) and BCL-2 gene overexpression presented worse PFS (p =0.043, {[}HR] 2.008, 95% CI: 1.02-3.95). At multivariate analysis, OCT-1 overexpression was associated with poor PFS (p =0.035, {[}HR] 2.22, 95% CI: 1.06-4.67).ConclusionIn this study, we showed that overexpression of OCT1 gene was an independent prognostic factor of adverse outcomes in DLBCL. (AU)

• Processo FAPESP: 10/51625-2 - Detecção da expressão dos genes associados a resistência a múltipla droga, Oct-1 e MDR-1 e do gene bcl-2 em linfoma difuso de grandes células B
• Beneficiário: Juliana Pereira
• Modalidade de apoio: Auxílio à Pesquisa - Regular